Skip to main content
Year archive

MAYNE PHARMA GROUP LIMITED — 2021 filings

All 38 regulatory filings released by MAYNE PHARMA GROUP LIMITED (MYX) in 2021, sourced directly from the official regulator.

38 Filings
2021 Period
2021 filings (38)
Filing Released Lang
Change of Director's Interest Notice 2 pages 254.8KB
Director's Dealing
2021-12-06 English
Notification regarding unquoted securities - MYX 7 pages 30.1KB
Share Issue/Capital Change
2021-12-02 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings
2021-11-29 English
TGA approval of novel oral contraceptive NEXTSTELLIS 2 pages 213.8KB
Capital/Financing Update
2021-11-28 English
2021 Mayne Pharma AGM Speeches 21 pages 952.6KB
AGM Information
2021-11-22 English
Results of Meeting 2 pages 196.9KB
Declaration of Voting Results & Voting Rights Announcements
2021-11-22 English
2021 AGM Notice of Meeting and Shareholder Pack 18 pages 5.7MB
AGM Information
2021-10-21 English
Annual Report to shareholders 98 pages 4.4MB
Annual Report
2021-10-18 English
2021 Corporate Governance Statement and Appendix 4G 28 pages 923.1KB
Governance Information
2021-10-18 English
MAYNE PHARMA provides FDA update on generic NUVARING 1
Regulatory Filings
2021-10-06 English
Initial Director's Interest Notice 2 pages 136.8KB
Director's Dealing
2021-10-04 English
Mayne Pharma appoints new Director 2 pages 146.0KB
Board/Management Information
2021-10-03 English
Final Director's Interest Notice (x2) 4 pages 378.0KB
Director's Dealing
2021-10-03 English
Mayne Pharma adds generic ABSORICA to US portfolio 2 pages 152.4KB
Capital/Financing Update
2021-09-28 English
Notification regarding unquoted securities - MYX 7 pages 30.1KB
Share Issue/Capital Change
2021-09-26 English
Change of Director's Interest Notice 2 pages 189.0KB
Director's Dealing
2021-09-01 English
Appendix 4E and Statutory Accounts 77 pages 2.0MB
Annual Report
2021-08-26 English
2021 Full Year Media Release 6 pages 395.5KB
Annual Report
2021-08-26 English
2021 Full Year Investor Presentation 30 pages 1.1MB
Investor Presentation
2021-08-26 English
Mayne Pharma board renewal and new Chairman 2 pages 150.8KB
Board/Management Information
2021-08-25 English
Notification of cessation of securities - MYX 4 pages 24.4KB
Transaction in Own Shares
2021-08-02 English
Class action proceeding 1 page 114.7KB
Legal Proceedings Report
2021-08-02 English
Change of Director's Interest Notice 2 pages 193.3KB
Director's Dealing
2021-08-01 English
Lapse of performance rights 1 page 185.1KB
Regulatory Filings
2021-08-01 English
NEXTSTELLIS oral contraceptive now available in the US 3 pages 127.9KB
Regulatory Filings
2021-06-20 English
Mayne Pharma expands Australian dermatology portfolio 2 pages 158.9KB
Capital/Financing Update
2021-06-20 English
NEXTSTELLIS FDA exclusivity & phase III data published 3 pages 220.3KB
Capital/Financing Update
2021-05-26 English
Becoming a substantial holder 17 pages 1.2MB
Regulatory Filings
2021-05-13 English
Appendix 2A and Notice under ASX Listing Rule 3.10A 16 pages 881.1KB
Share Issue/Capital Change
2021-05-12 English
Change in substantial holding 8 pages 292.1KB
Regulatory Filings
2021-04-19 English
FDA approval of novel oral contraceptive NEXTSTELLIS 3 pages 118.4KB
Regulatory Filings
2021-04-15 English
Appendix 3G 14 pages 402.5KB
Capital/Financing Update
2021-03-18 English
New data on NEXTSTELLIS presented at ISSWSH conference 2 pages 152.6KB
Regulatory Filings
2021-03-07 English
Change in substantial holding 7 pages 988.9KB
Major Shareholding Notification
2021-03-04 English
Half Yearly Report and Accounts 40 pages 1.8MB
Interim / Quarterly Report
2021-02-23 English
2021 Half Year Media Release 6 pages 313.3KB
Interim / Quarterly Report
2021-02-23 English
2021 Half Year Investor Presentation 26 pages 2.9MB
Investor Presentation
2021-02-23 English
Mayne Pharma launches Microgestin 24 FE tablets in the US 2 pages 168.3KB
Regulatory Filings
2021-01-06 English